Zenas BioPharma (NASDAQ:ZBIO) & Lyell Immunopharma (NASDAQ:LYEL) Head to Head Survey

Zenas BioPharma (NASDAQ:ZBIO) and Lyell Immunopharma (NASDAQ:LYEL) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Insider and Institutional Ownership

66.0% of Lyell Immunopharma shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Zenas BioPharma and Lyell Immunopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1	2	6	0	2.56
Lyell Immunopharma	1	1	6	1	2.78

Zenas BioPharma currently has a consensus price target of $45.71, suggesting a potential upside of 39.03%. Lyell Immunopharma has a consensus price target of $40.86, suggesting a potential upside of 184.32%. Given Lyell Immunopharma’s stronger consensus rating and higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Zenas BioPharma.

Profitability

This table compares Zenas BioPharma and Lyell Immunopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-122.45%	-58.04%
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%

Risk & Volatility

Zenas BioPharma has a beta of -1.04, indicating that its share price is 204% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500.

Valuation & Earnings

This table compares Zenas BioPharma and Lyell Immunopharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$1.00 million	2,143.02	-$377.74 million	($8.99)	-3.66
Lyell Immunopharma	$40,000.00	8,801.62	-$274.45 million	($12.83)	-1.12

Lyell Immunopharma has lower revenue, but higher earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Lyell Immunopharma beats Zenas BioPharma on 9 of the 14 factors compared between the two stocks.

About Zenas BioPharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

About Lyell Immunopharma

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.